New drug donanemab is 'a turning point in the fight against Alzheimer’s'
New drug donanemab is 'a turning point in the fight against Alzheimer’s' .Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, has called breakthrough Alzheimer's drug donanemab, 'a turning point', as the full trial results were revealed.